Key result
PET/CT negativity using liver uptake as a cutoff after chemoimmunotherapy predicted a higher 5-year progression-free survival compared to PET positivity (99% vs 68%; P<.001).
Why the study?
Does [18F]FDG PET/CT after chemoimmunotherapy predict survival in patients with primary mediastinal large B-cell lymphoma?
Cohort (n=115)
Yes
Does [18F]FDG PET/CT after chemoimmunotherapy predict survival in patients with primary mediastinal large B-cell lymphoma?
Absolute Event Rate: 99% vs 68%
p-value: p=<.001
[18F]FDG PET/CT using liver uptake as a cutoff effectively predicts 5-year progression-free and overall survival in patients with primary mediastinal large B-cell lymphoma after chemoimmunotherapy.
No takes yet. Share an insight, caveat, or question.
PET negativity after chemoimmunotherapy may identify low-risk PMLBCL; leaves open whether RT can be safely omitted in prospective trials.
Martelli et al. (2014) conducted a cohort in Primary mediastinal large B-cell lymphoma (PMLBCL) (n=115). PET/CT negativity (using liver uptake cutoff) vs. PET/CT positivity was evaluated on 5-year progression-free survival (p=<.001). PET/CT negativity using liver uptake as a cutoff after chemoimmunotherapy predicted a higher 5-year progression-free survival compared to PET positivity (99% vs 68%; P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: